Despite the fact that hepatitis C virus (HCV) persists chronically in about 80 percent of those infected, some liver cells remain free of the virus even after many years. Now Sung Key Jang of Pohang University of Science ...
not rated yet |
0
Sexual transmission of hepatitis C virus (HCV) is considered rare. But a new study by researchers at Mount Sinai School of Medicine, working with the Centers for Disease Control and Prevention (CDC), provides substantial ...
5 / 5 (1) |
0
Researchers from the Mayo Clinic confirm that ultrasound-based transient elastography (TE) provides excellent diagnostic accuracy for detecting cirrhosis due to recurrent infection with hepatitis C virus (HCV) infection following ...
4 / 5 (1) |
0
A new classification for diagnosing fibrosis in patients with chronic hepatitis C virus (HCV) has shown to be as accurate as currently used algorithms, but required no further liver biopsy. The study appearing in the January ...
not rated yet |
0
(HealthDay)—The lack of a hepatitis C virus (HCV) RNA test for approximately one-half of persons newly reported as HCV infected suggests that testing and reporting must improve to detect all persons with ...
not rated yet |
0
New research shows that older Americans with cirrhosis have significantly worse health status and greater functional disability compared to those without this potentially deadly disease. In fact, findings now published in ...
not rated yet |
0
A new study finds liver cancer incidence rates continue to increase in some low-risk parts of the world such as North America, and are decreasing in some of the highest risk countries of Asia. Despite this, the incidence ...
not rated yet |
0
[EMBARGOED FOR JULY 18, 2012] In a long-term study of people infected with the hepatitis C virus (HCV), researchers found increased deaths from both liver-related and non-liver related diseases in patients with active infections ...
not rated yet |
0
US biotech firm Gilead Sciences announced plans Monday to acquire rival Pharmasset, a group specializing in treatments for AIDS and hepatitis, for $11 billion.
3 / 5 (1) |
0
British researchers have identified specific resistance mutations for two classes of p7 inhibitor, which may explain their lack of effectiveness in clinical trials combined with current standard of care. Study results support ...
not rated yet |
0
The University of Liverpool has launched an iphone app, HEP i-chart, that provides Hepatitis C (HCV) patients with quick and easy access to the latest information about drug interactions.
not rated yet |
0
